(Lung Cancer) Is Ramucirumab (Cyramza) Plus Erlotinib Effective? RELAY Phase 3 Trial Results
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- December 16, 2019
- 2 min read
Updated: January 27, 2020
On October 4, 2019, Kazuhiko Nakagawa published results in The Lancet Oncology from the RELAY Phase 3 clinical trial evaluating the efficacy and safety of ramucirumab (Cyramza, anti-VEGFR antibody) plus erlotinib (EGFR tyrosine kinase inhibitor) in treatment-naive EGFR-positive non-small cell lung cancer (NSCLC) patients.
Trial Design:
The RELAY Phase 3 trial was an international multicenter, double-blind study. Treatment-naive EGFR-positive NSCLC patients (N=449) were randomized to:
- Ramucirumab group (N=224): Ramucirumab 10 mg/kg every 2 weeks + erlotinib 150 mg once daily
- Placebo group (N=225): Placebo every 2 weeks + erlotinib 150 mg once daily
Primary endpoints were PFS and safety; secondary endpoints were OS and ORR.
Background: VEGF and EGFR inhibitors had individually demonstrated efficacy in EGFR-positive NSCLC patients in both preclinical and clinical settings. The RELAY trial was designed to evaluate whether combining a VEGFR antibody with an EGFR TKI would improve outcomes.
Results at median follow-up of 20.7 months:
- Median PFS: Ramucirumab 19.4 months vs. placebo 12.4 months
- 41% reduction in progression risk — statistically significant improvement
Safety:
Grade 3–4 adverse events: Ramucirumab 72% (N=159) vs. placebo 54% (N=121). Most common Grade 3–4 adverse events: Ramucirumab arm — hypertension 24% (N=52), dermatitis 15% (N=30); Placebo arm — dermatitis 9% (N=20), ALT elevation 8% (N=17).
Serious adverse events: Ramucirumab 29% (N=65) vs. placebo 21% (N=47). Most common serious events: Ramucirumab arm — pneumonia 3% (N=7), cellulitis (N=4), pneumothorax (N=4); Placebo arm — fever 1% (N=3), pneumonia 1% (N=3).
Conclusion: Based on the RELAY trial results, Kazuhiko Nakagawa concluded that ramucirumab plus erlotinib significantly improved PFS in treatment-naive EGFR-positive NSCLC patients, with acceptable tolerability.
Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. Please consult your healthcare provider for medical decisions.
Source: Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Oct 4. doi:10.1016/S1470-2045(19)30634-5.
Lung Cancer | Ramucirumab | Cyramza | Erlotinib | RELAY
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5